1
Participants
Start Date
February 26, 2024
Primary Completion Date
March 14, 2024
Study Completion Date
March 20, 2024
electroencephalogram biofeedback
EB is conducted for 20 minutes per section with two sections per day in the primary efficacy endpoint.
electrical brain stimulation
EBS is conducted for 20 minutes per section per day in the primary efficacy endpoint.
ultra-low frequency transcranial magnetic stimulation
ULF-TMS is conducted mainly for the left side of the participant's brain for 20 minutes per section per day in the primary efficacy endpoint.
Sertraline Hydrochloride
Sertraline is taken in the morning for 150 mg per day.
Clonazepam
Clonazepam is taken in the morning for 1 mg per day.
Alprazolam
Alprazolam is introduced near the end of the primary efficacy endpoint for 0.4 mg per night.
Metoprolol
Metoprolol is introduced at the secondary efficacy endpoint starting with 47.5 mg per night and increase to 95 mg per night.
Olanzapine
Olanzapine is taken throughout the trial with 7.5 mg per night at first, and increases to 10 mg per night after the cocktail therapy.
Pravastatin Sodium 20 MG
Pravastatin sodium is introduced in the secondary efficacy endpoint with 20 mg per night.
Sacubitril Valsartan Sodium Hydrate
Sacubitril valsartan sodium is introduced in the secondary efficacy endpoint with 100 mg per day.
Residential Address, Chongqing
First Affiliated Hospital of Chongqing Medical University
OTHER
Pachankis, Yang I., M.D.
INDIV